rexahn pharmaceuticals inc (RNN) Key Developments
Rexahn Pharmaceuticals, Inc. Reports Earnings Results for the Year Ended December 31, 2013
Mar 27 14
Rexahn Pharmaceuticals, Inc. reported earnings results for the year ended December 31, 2013. For the period, the company's net loss was $9.5 million, or $0.07 loss per share, compared to a net loss of $6.23 million, or $0.06 loss per share, for the year ended December 31, 2012. Loss from operations for the year ended December 31, 2013 was $7.98 million, compared to a loss from operations of $6.58 million for the year ended December 31, 2012. Total assets as of December 31, 2013 were $19.56 million, compared to $14.92 million as of December 31, 2012.
Rexahn Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014
Mar 12 14
Rexahn Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014. Venue: New York Academy of Sciences, New York, United States. Presentation Date & Speakers: Mar-19-2014, Vikas Sharma, Director, Business Development.
Rexahn Pharmaceuticals, Inc. Announces Initial Results from Phase I Trial of Supinoxin (RX-5902) for Solid Cancer Tumors
Mar 11 14
Rexahn Pharmaceuticals, Inc. announced initial data for the Phase I dose-escalation clinical trial of Supinoxin (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors. The study is still ongoing and the maximal tolerated dose (MTD) has not yet been achieved. Three dosing cycles have been completed (25, 50 and 100 mg) and no drug related adverse events have been reported. The fourth dosing cycle (150 mg) has been initiated. Two patients have received 2 cycles of treatment and one patient has received 6 cycles of treatment. Pharmacokinetic analysis has shown that Supinoxin(TM) displays dose-proportional exposure and an estimated oral bioavailability of 51%. The pharmacokinetic profile of Supinoxin is similar to what has been seen in preclinical studies. The Phase I trial of Supinoxin, which was initiated in August 2013, is a dose-escalation study which will evaluate the safety, tolerability, dose-limiting toxicities and MTD in patients with solid cancer tumors that have previously failed treatment with approved therapies and shown progression of disease. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted in three clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by and 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The trial is using an accelerated dose-escalation design: one patient is treated per dose cycle until a grade 2 related adverse event occurs then three patients will be treated per dose cycle. The decision to escalate dose is made by the DMSB after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phospho-P68. Supinoxin (RX-5902) is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68). P-p68, which is selectively expressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung. In preclinical studies, Supinoxin has been shown to inhibit proliferation of cancer cells in 18 human cancer cell lines including breast, colon, pancreas, ovarian, and stomach cancers, and showed potent activity in drug-resistant cancer cells. In an animal model, where human cancer cells from melanoma, pancreas, renal or ovarian cancers were grafted into animals, treatment with Supinoxin resulted in a significant reduction in tumor growth.
Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
Mar 3 14
Rexahn Pharmaceuticals, Inc. announced the appointment of Mark P. Carthy to the company's Board of Directors. Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC.
Rexahn Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 02:00 PM
Feb 20 14
Rexahn Pharmaceuticals, Inc. Presents at 26th Annual ROTH Conference, Mar-11-2014 02:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Peter D. Suzdak, PhD, Chief Executive Officer.